title: [Chylorrhea after left nephroureterectomy].
abstract: A 74-year old man developed chylorrhea after transperitoneal left nephrouretectomy for renal pelvic malignancy. This patient had received ureterolithotomy for the left ureteral stones twice about 30 years ago. He was treated successfully with peripheral parenteral nutrition and subcutaneous administration of Octreotide, an available somatostatin analog with a long half-life. Postoperative chylorrhea is a rare complication that may result in serious complications such as nutritional and immunological disturbance, due to a loss of body proteins and lymphocytes. Chylorrhea, therefore, should be treated adequately and immediately at the time of diagnosis. Octreotide, which is effective in the treatment of chylorrhea and has no adverse effects, is considered a therapeutic choice.
authors.affiliation: Department of Urology, Yokohama City Minato Red Cross Hospital.
authors.forename: Kimito
authors.initials: K
authors.lastname: Osaka
authors.forename: Masataka
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fujikawa
authors.forename: Hideki
authors.initials: H
authors.lastname: Ouchi
authors.forename: Akira
authors.initials: A
authors.lastname: Iwasaki
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002915:Chylous Ascites / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery; D007682:Kidney Pelvis; D008297:Male; D009392:Nephrectomy; D015282:Octreotide / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives; D016896:Treatment Outcome; D014513:Ureter / Q000601:surgery*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013004:Somatostatin; D015282:Octreotide